AFFILIATIONS
1 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, University Hospital Frankfurt, Frankfurt am Main, Germany
2 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, Université Paris-Saclay, Paris, France
3 Broad Institute, Cambridge, United States
4 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, United States, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
7 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
8 Dana-Farber Cancer Institute, Boston, United States
9 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
10 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
11 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
12 Broad Institute, Cambridge, United States
13 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
14 Dana-Farber Cancer Institute, Boston, United States
15 Dana-Farber Cancer Institute, Boston, United States
16 Dana-Farber Cancer Institute, Boston, United States
17 Dana-Farber Cancer Institute, Boston, United States
18 Dana-Farber Cancer Institute, Boston, United States
19 Dana-Farber Cancer Institute, Boston, United States
20 Dana-Farber Cancer Institute, Boston, United States
21 Dana-Farber Cancer Institute, Boston, United States
22 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
23 Broad Institute, Cambridge, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
ABSTRACT
Background: The genomic determinants of treatment failure and their impact on clonal evolution under early therapeutic intervention in high-risk smoldering myeloma (HR-SMM) remain poorly understood. Although several genomic alterations have been associated with progression in untreated SMM, it is unclear whether these markers retain prognostic significance following therapy. We therefore performed baseline genomic profiling of 115 patients with HR-SMM enrolled in early-intervention clinical trials, complemented by longitudinal genomic analyses, to identify predictors of progression and characterize clonal evolution under treatment.
Methods: We performed baseline whole-genome sequencing (WGS; n=88) and incorporated previously published whole-exome sequencing (WES; n=27) data from 115 patients with HR-SMM enrolled in five early-intervention clinical trials. Patients received preventive-intent regimens (lenalidomide-dexamethasone [Rd], ixazomib-Rd, elotuzumab-Rd, or daratumumab; n=66) or curative-intent regimens (daratumumab, lenalidomide, bortezomib, and dexamethasone [DRVd] or teclistamab; n=49). Associations between genomic alterations and progression to multiple myeloma (MM) according to SLiM-CRAB criteria, biochemical progression-free survival (PFS), and time to next therapy (TTNT) were evaluated using mixed-effects Cox proportional hazards models adjusted for treatment intent. Longitudinal WGS was performed in 17 patients with serial samples collected before, during, and after therapy (n=38) to characterize clonal evolution, and these data were compared with data from 11 untreated HR-SMM patients.
Results: At a median follow-up of 4 years, 18 patients progressed according to SLiM-CRAB criteria, 62 experienced biochemical progression, and 33 initiated subsequent therapy. Existing SMM risk models (e.g. IMWG 2/20/20 classification, genomic MM-like score) were not consistently associated with outcome following treatment. Instead, we found several genomic markers predicting progression after early intervention in SMM.
The IMS/IMWG 2025 genomic high-risk classification demonstrated the strongest association with progression to symptomatic MM (HR 5.9, 95% CI 2.2–15.4, p=0.0003). In addition, del(6q) independently predicted shorter SLiM-CRAB PFS (HR 3.4, 95% CI 1.3–9.1, p=0.01). TP53 alterations and DIS3 mutations were independently associated with inferior biochemical PFS (HR 3.7, p=0.007 and HR 3.3, p=0.003, respectively), while del(16q) and del(6q) predicted shorter TTNT (HR 3.1, p=0.02 and HR 2.3, p=0.04, respectively).
Longitudinal analyses revealed distinct evolutionary trajectories according to treatment intent. Acquisition of additional myeloma driver alterations was observed in 6/10 patients receiving preventive-intent therapy compared with only 1/7 receiving curative-intent therapy. Expansion or acquisition of del(1p), including conversion to IMS/IMWG 2025 genomic high-risk disease, occurred exclusively in the preventive-intent cohort and closely mirrored patterns observed in untreated SMM. In contrast, curative-intent regimens were associated with a decrease in canonical myeloma driver alterations (e.g., amp(1q), DIS3) and emergence of alternative subclones, including alterations previously linked to treatment resistance in MM. No recurrent genomic resistance mechanism was identified across patients.
Conclusion: Genomic predictors of progression in treated HR-SMM differ from traditional risk models developed in untreated disease and instead resemble high-risk genomic features associated with adverse outcome in overt MM, consistent with a shift from genomic determinants of natural disease evolution to those associated with poor outcome after therapy. Longitudinal profiling further demonstrates that preventive-intent therapy largely recapitulates the natural evolutionary trajectory of SMM, supporting a model in which early intervention delays rather than redirects disease evolution. In contrast, curative-intent regimens can reshape clonal architecture through a decrease in established myeloma drivers and emergence of alternative subclones. Together, these findings provide the first genomic landscape of progression under therapy, establish a framework for genomic risk stratification in treated HR-SMM, and support the concept of HR-SMM as a transitional disease state in which genomic determinants of natural progression coexist with features associated with adverse outcome under treatment.